| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-10-15 | Botox® (onabotulinumtoxinA) | urinary incontinence in female patients with overactive bladder (OAB) symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication | 3 | Allergan (Ireland) | |
| 2015-10-15 | GLPG2665 | cystic fibrosis | preclinical | Galapagos (Belgium) | Rare diseases - Genetic diseases |
| 2015-10-15 | Hepatic CHEMOSAT® Delivery System for Melphalan | unresectable hepatocellular carcinoma | 2 | Delcath Systems (USA - NY) | Cancer - Oncology |
| 2015-10-15 | QVM149 | asthma | Novartis (Switzerland) Vectura (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases | |
| 2015-10-15 | ISIS-SMN Rx (antisense oligonucleotide targeted to the SMN2 gene) | spinal muscular atrophy | 3 | Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2015-10-15 | etirinotecan pegol (NKTR-102) | advanced breast cancer | 3 | Nektar Therapeutics (USA - CA) | Cancer - Oncology |
| 2015-10-15 | KUR-211 | lumber interbody spinal fusion | preclinical | Kuros Biosciences (Switzerland) | Bone diseases - Regenerative medicine |
| 2015-10-14 | bone marrow-derived cellular therapy | progressive multiple sclerosis | 2 | NHS (UK) Bristol Royal Hospital for Children (UK) University of Bristol (UK) University of Nottingham (UK) NHS Blood and Transplant (UK) | Neurodegenerative diseases |
| 2015-10-14 | Delcath Hepatic Delivery System (Melphalan/HDS) | melanoma liver metastases | 3 | Delcath Systems (USA - NY) | Cancer - Oncology |
| 2015-10-14 | ALN-TTRsc02 | transthyretin-mediated amyloidosis (ATTR) | preclinical | Alnylam Therapeutics (USA - MA) | Rare diseases - Genetic diseases |
| 2015-10-14 | sacituzumab govitecan - IMMU-132 | triple-negative breast cancer (TNBC) | 3 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2015-10-13 | ADX71441 | alcohol use disorder | preclinical | Addex Therapeutics (Switzerland) National Institute on Alcohol Abuse and Alcoholism (NIAAA) (USA) | |
| 2015-10-13 | Cinryze® | acute antibody-mediated rejection in kidney transplant patients | 3 | Shire (UK - USA) | Transplantation - Renal diseases - Kidney diseases |
| 2015-10-13 | Reversir™ Platform | Alnylam Therapeutics (USA - MA) | Technology - Services | ||
| 2015-10-13 | Bis-RNAi™ Platform | Alnylam Therapeutics (USA - MA) | Technology - Services | ||
| 2015-10-13 | lefamulin (BC 3781) | community-acquired bacterial pneumonia (CABP) | Nabriva Therapeutics (Austria) | Infectious diseases | |
| 2015-10-13 | lefamulin (BC 3781) | community-acquired bacterial pneumonia (CABP) | Nabriva Therapeutics (Austria) | Infectious diseases | |
| 2015-10-13 | lefamulin (BC 3781) | community-acquired bacterial pneumonia (CABP) | Nabriva Therapeutics (Austria) | Infectious diseases | |
| 2015-10-13 | OATD-01 | asthma | 1 | OncoArendi Therapeutics (Poland) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2015-10-13 | selinexor (KPT-330 - (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide) | dedifferentiated liposarcoma | 2-3 | Karyopharm Therapeutics (USA - MA) | Cancer - Oncology |
